Skip to main content
SpringerLink
Log in

The Anticonvulsant Effect of a Novel Indole-Related Compound in the Kainate-Induced Status Epilepticus in Mice: The Role of the Antioxidant and Anti-inflammatory Mechanism

  • Original Paper
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

We synthesized a series of novel indole compounds containing aroylhydrazone moieties and evaluated them in mice to check their anticonvulsant activity. In the present study the most potent C3-modified derivative 3e, containing 2-furyl fragment was evaluated in kainate (KA)-induced status epilepticus (SE) and the consequences on oxidative stress and inflammation in the hippocampus in mice were explored. Melatonin was used as positive control while the melatonin receptor antagonist Luzindol was studied alone or in combination with melatonin or 3e, respectively. After intraperitoneal (i.p.) pre-treatment with melatonin 3e, Luzindol + melatonin and Luzindol + 3e for 7 days (melatonin and 3e—30 mg kg−1 or 60 mg kg−1, Luzindol 10 mg kg−1) the animals were i.p. injected with KA (30 mg kg−1, i.p.). The 3e decreased the SE-induced seizure intensity while melatonin suppressed seizures at the higher dose of 60 mg kg−1. Luzindol blocked the anticonvulsant effect of both Mel and 3e. The dose-dependent antioxidant effect of 3e measured by reduced glutathione (GSH) and total GSH in the hippocampus, was comparable to the effect of melatonin. Luzindol fully blocked the effect of melatonin but affected partially the antioxidant activity of 3e. The KA-induced increased amplifier of neuroinflammation high-mobility group box protein 1 (HMGB1) was neither alleviated by melatonin, nor by 3e. The activation by this DNA-binding protein receptor for advanced glycation end products (RAGE) was not affected by SE, melatonin and 3e pre-treatment. Our results suggest that the novel indole derivate 3e, containing 2-furyl fragment, might be clinically useful as an adjunct therapy against SE and concomitant oxidative stress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Agrawal N, Govender S (2011) Epilepsy and neuropsychiatric comorbidities. Adv Psychiatric Treat 17:44–53. https://doi.org/10.1192/apt.bp.108.006510

    Article  Google Scholar 

  2. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH (2015) A definition and classification of status epilepticus: report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 56:1515–1523. https://doi.org/10.1111/epi.13121

    Article  PubMed  Google Scholar 

  3. Kaneko Y, Pappas C, Malapira T, Vale F, Tajiri N, Borlongan CV (2017) Extracellular HMGB1 modulates glutamate metabolism associated with Kainic acid-induced epilepsy-like hyperactivity in primary rat neural cells. Cell Physiol Biochem 41(3):947–959. https://doi.org/10.1159/000460513

    Article  CAS  PubMed  Google Scholar 

  4. Baxevanis AD, Landsman D (1995) The HMG-1 box protein family: classification and functional relationships. Nucleic Acids Res 23:1604–1613. https://doi.org/10.1093/nar/23.9.1604

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ravizza T, Vezzani A (2013) Receptor for advanced glycation endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiol Dis 58:102–114. https://doi.org/10.1016/j.nbd.2013.03.006

    Article  CAS  PubMed  Google Scholar 

  6. Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q (2013) Melatonin in Alzheimer’s disease. Int J Mol Sci 14(7):14575–14593. https://doi.org/10.3390/ijms140714575

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Molina-Carballo A, Muñoz-Hoyos A, Reiter RJ, Sánchez-Forte M, Moreno-Madrid F, Rufo-Campos M, Molina-Font JA, Acuna-Castroviejo D (1997) The utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years’ experience. J Pineal Res 23:97–105. https://doi.org/10.1111/j.1600-079X.1997.tb00341.x

    Article  CAS  PubMed  Google Scholar 

  8. Petkova Zl, Tchekalarova J, Pechlivanova D, Moyanova Sl, Kortenska L, Mitreva R, Popov D, Markova P, Lozanov V, Atanasova D, Lazarov N, Stoynev A (2014) Treatment with melatonin after status epilepticus attenuates seizure activity and neuronal damage but does not prevent the disturbance in diurnal rhythms and behavioral alterations in spontaneously hypertensive rats in kainate model of temporal lobe epilepsy. Epilepsy Behav 31:198–208. https://doi.org/10.1016/j.yebeh.2013.12.013

    Article  Google Scholar 

  9. Rocha AKA, Cipolla-Neto J, Amado D (2018) Epilepsy: neuroprotective, anti-inflammatory, and anticonvulsant effects of melatonin. Melatonin: medical uses and role in health and disease, Chap. 8, Nova Science Publishers, Inc. ISBN: 978-1-53612-987-8

  10. Srinivasan V, Cardinali DP, Srinivasan US et al (2011) Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection. Ther Adv Neurol Disord 4(5):297–317. https://doi.org/10.1177/1756285611406166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tchekalarova J, Petkova Z, Pechlivanova D, Sl Moyanova, Kortenska L, Mitreva R, Lozanov V, Atanasova D, Lazarov N, Al Stoynev (2013) Prophylactic treatment with melatonin after status epilepticus: effects on epileptogenesis, neuronal damage and behavioral changes in kainate model of temporal lobe epilepsy. Epilepsy Behav 27:174–187. https://doi.org/10.1016/j.yebeh.2013.01.009

    Article  PubMed  Google Scholar 

  12. Tchekalarova J, Moyanova S, De Fusco A, Ngomba RT (2015) The role of the melatoninergic system in epilepsy and comorbid psychiatric disorders. Brain Res Bull 119:80–92. https://doi.org/10.1016/j.brainresbull.2015.08.006

    Article  CAS  PubMed  Google Scholar 

  13. Yeganeh-Salehpour M, Mollica A, Momtaz S, Sanadgol N, Farzaei MH (2019) Melatonin and multiple sclerosis: from plausible neuropharmacological mechanisms of action to experimental and clinical evidence. Clin Drug Investig 39(7):607–624. https://doi.org/10.1007/s40261-019-00793-6

    Article  PubMed  Google Scholar 

  14. Atanasova M, Petkova Zl, Pechlivanova D, Dragomirova P, Blazhev, Tchekalarova J (2013) Strain differences in the effect of long-term treatment with melatonin on kainic acid-induced status epilepticus, oxidative stress and the expression of heat shock proteins. Pharmacol Biochem Behav 111:44–50. https://doi.org/10.1016/j.pbb.2013.08.006

    Article  CAS  PubMed  Google Scholar 

  15. Angelova V, Rangelov M, Todorova N, Dangalov M, Andreeva-Gateva P, Kondeva-Burdina M, Karabeliov V, Shivachev B, Tchekalarova J (2019) Discovery of novel indole-based aroylhydrazones as anticonvulsants: pharmacophore-based design. Bioorg Chem 90:103028. https://doi.org/10.1016/j.bioorg.2019.103028

    Article  CAS  PubMed  Google Scholar 

  16. Marchev S, Andreeva-Gateva P, Tzoneva R, Surcheva S, Tzonev A, Kamenova K, Angelova VT, Tchekalarova J, Vlaskovska M (2019) Analgesic activity of some aroylhydrazone-based molecular hybrids with antiseizure activity: in vivo and in silico evaluations. Biotechnol Biotechnol Equip 33:98–107. https://doi.org/10.1080/13102818.2018.1555009

    Article  CAS  Google Scholar 

  17. Andreeva-Gateva P, Tchekalarova J, Kamenova K, Angelova VT, Surcheva SI (2021) Aryl hydrocarbon receptors in indole derivative treated mice: Neuropharmacological perspectives. Acta Medica Bulg 48(1):25–33. https://doi.org/10.2478/amb-2021-0004

    Article  Google Scholar 

  18. Tchekalarova J, Angelova V, Todorova N, Andreeva-Gateva P, Rangelov M (2019) Evaluation of the anticonvulsant effect of novel melatonin derivatives in the intravenous pentylenetetrazol seizure test in mice. Eur J Pharmacol 20:863:172684. https://doi.org/10.1016/j.ejphar.2019.172684

    Article  CAS  Google Scholar 

  19. Tchekalarova J, Ivanova N, Nenochovska Z, Tzoneva R, Stoyanova T, Uzunova V, Surcheva S, Tzonev A, Angelova V, Andreeva-Gateva P (2020) Evaluation of neurobiological and antioxidant effects of novel melatonin analogs in mice. Saudi Pharm J 28(12):1566–1579. https://doi.org/10.1016/j.jsps.2020.10.004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zeng L, Zhang H, Xu C, Bian Y, Xu X, Xi Q, Zhang RJ (2013) Zhejiang Univ-Sci B Biomed Biotechnol 14(11):1004–1012. https://doi.org/10.1631/jzus.B1300138

    Article  CAS  Google Scholar 

  21. Chen Y, Huang X-J, Yu N, Xie Y, Zhang K, Wen F et al (2015) HMGB1 contributes to the expression of P-glycoprotein in mouse epileptic brain through toll-like receptor 4 and receptor for advanced glycation end products. PLoS ONE 10:e0140918. https://doi.org/10.1371/journal.pone.0140918

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Fu L, Liu K, Wake H, Teshigawara K, Yoshino T, Takahashi H et al (2017) Therapeutic effects of anti-HMGB1 monoclonal antibody on pilocarpineinduced status epilepticus in mice. Sci Rep 7:1179. https://doi.org/10.1038/s41598-017-01325-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, Rossetti C, Molteni M, Casalgrandi M, Manfredi A, Bianchi ME, Vezzani A (2010) Nat Med 16:413–419. https://doi.org/10.1038/nm.2127

    Article  CAS  PubMed  Google Scholar 

  24. Iori V, Maroso M, Rizzi M, Iyer AM, Vertemara R, Carli M, Vezzani A (2013) Receptor for advanced glycation endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiol Dis 58:102–114. https://doi.org/10.1016/j.nbd.2013.03.006

    Article  CAS  PubMed  Google Scholar 

  25. Ito M, Takahashi H, Yano H, Shimizu YI, Yano Y, Ishizaki Y et al (2017) High mobility group box 1 enhances hyperthermia-induced seizures and secondary epilepsy associated with prolonged hyperthermia-induced seizures in developing rats. Metab Brain Dis 32:2095–2104. https://doi.org/10.1007/s11011-017-0103-4

    Article  CAS  PubMed  Google Scholar 

  26. Vezzani A, Granata T (2005) Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 46:1724–1743. https://doi.org/10.1111/j.1528-1167.2005.00298.x

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Science Fund of Bulgaria, Grant DN13/16 21.12.2017.

Author information

Authors and Affiliations

  1. Institute of Neurobiology, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bl. 23, 1113, Sofia, Bulgaria

    Jana Tchekalarova & Tsveta Stoyanova

  2. Institute of Biophysics and Biomedical Engineering, BAS, Sofia, Bulgaria

    Rumiana Tzoneva

  3. Department of Chemistry, Faculty Pharmacy, Medical University-Sofia (MU-Sofia), Sofia, Bulgaria

    Violina Angelova

  4. Department of Pharmacology and Toxicology, Medical Faculty, Medical University of Sofia, Sofia, Bulgaria

    Pavlina Andreeva-Gateva

Authors
  1. Jana Tchekalarova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsveta Stoyanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rumiana Tzoneva
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Violina Angelova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pavlina Andreeva-Gateva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jana Tchekalarova.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Raw O.D. values for all standards and experimental samples for total GSH measurements. Supplementary file1 (XLS 66 kb)

11064_2021_3447_MOESM2_ESM.xls

Raw O.D. values for all standards and experimental samples for reduced GSH measurements. Supplementary file1 (XLS 66 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tchekalarova, J., Stoyanova, T., Tzoneva, R. et al. The Anticonvulsant Effect of a Novel Indole-Related Compound in the Kainate-Induced Status Epilepticus in Mice: The Role of the Antioxidant and Anti-inflammatory Mechanism. Neurochem Res 47, 327–334 (2022). https://doi.org/10.1007/s11064-021-03447-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-021-03447-2

Keywords

Search

Navigation